Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces.

Recent advances in spatial transcriptomics (STs) enable gene expression measurements from a tissue sample while retaining its spatial context. This technology enables unprecedented in situ resolution of the regulatory pathways that underlie the heterogeneity in the tumor as well as the tumor microenvironment (TME). The direct characterization of cellular co-localization with spatial technologies facilities quantification of the molecular changes resulting from direct cell-cell interaction, as it occurs in tumor-immune interactions. We present SpaceMarkers, a bioinformatics algorithm to infer molecular changes from cell-cell interactions from latent space analysis of ST data. We apply this approach to infer the molecular changes from tumor-immune interactions in Visium spatial transcriptomics data of metastasis, invasive and precursor lesions, and immunotherapy treatment. Further transfer learning in matched scRNA-seq data enabled further quantification of the specific cell types in which SpaceMarkers are enriched. Altogether, SpaceMarkers can identify the location and context-specific molecular interactions within the TME from ST data.

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests E.J.F. is on the Scientific Advisory Board of Viosera Therapeutics and is a paid consultant for Merck and Mestag Therapeutics. W.J.H. reports royalties from Rodeo/Amgen; grants from Sanofi and NeoTX; and consulting fees from Exelixis outside the submitted work. E.M.J. reports other support from Abmeta, personal fees from Achilles, personal fees from DragonFly, other support from Parker Institute, grants and other support from Lustgarten, personal fees from Carta and Bluedot, grants and other support from Genentech, and grants and other support from Break Through Cancer outside the submitted work. S.R.W., C.R.U., J.C., A.H., and Z.W.B. are equity stockholders and employees of 10x Genomics. L.Z. receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. L.Z. is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Natera, Novagenesis, Snow Lake Captials, Tempus, Amberston, and Mingruizhiyao. L.Z. holds shares at Alphamab and Mingruizhiyao. M.Y. reports grants and research support from Bristol-Myers Squibb, Incyte, and Genentech as well as honoraria from Genentech, Exelixis, Eisai, AstraZeneca, Replimune, and Hepion. C.S.M. reports research funding from Pfizer, AstraZeneca, BMS, and GSK/Tesaro and serves on the advisory boards of Bristol Myers Squibb (not paid), Seattle Genetics, Genomic Health, and Athenex. R.A.A. receives research support from Bristol-Myers Squibb, RAPT therapeutics, Stand up to Cancer, and the National Institutes of Health and serves on the advisory boards for Bristol-Myers Squibb, Merck SD, and AstraZeneca. A.S.P. is a consultant to AsclepiX Therapeutics and CytomX Therapeutics; he is the founder and Chief Scientific Advisor of AsclepiX Therapeutics; he receives research grants from AstraZeneca and Boehringer Ingelheim. The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.